Free Trial
→ Bank of America: 'Digital Dollar Inevitable' (From Decentralized Masters) (Ad)tc pixel
OTCMKTS:VAXX

Vaxxinity Q2 2023 Earnings Results & Report

Vaxxinity logo
$0.02 +0.01 (+14,900.00%)
As of 11/2/2026 10:26 AM Eastern

Vaxxinity beat analyst earnings expectations in its Q2 2023 results, released August 9, 2023. The company reported EPS of -$0.11 versus the -$0.16 consensus estimate.

Research:Profile

Earnings Announcement Details

Quarter
Q2 2023
Report Date

Vaxxinity EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.16
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Vaxxinity Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Vaxxinity's next earnings date is estimated for Wednesday, November 11, 2026, based on past reporting schedules.

Conference Call Resources

Vaxxinity Q2 2023 Earnings FAQ

Vaxxinity (OTCMKTS:VAXX) reported earnings of -$0.11 per share for Q2 2023, beating the consensus estimate of -$0.16. The report was announced on Wednesday, August 9, 2023.

Vaxxinity's next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Vaxxinity on the company's earnings history page.

Vaxxinity Earnings Headlines

Vaxxinity (OTCMKTS:VAXX) Shares Cross Above Two Hundred Day Moving Average - Here's What Happened
October 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31160852
Vaxxinity Inc.
May 25, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/vaxx/financials
The 401k Email 70 Million Investors Might Delete
An email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will delete it without a second look. Larry Benedict says that would be a mistake. He calls this the decade's biggest opportunity and is naming the one ticker to watch before it arrives. Watch his free breakdown now.tc pixel
 |  Brownstone Research (Ad)
Brain health
October 24, 2024  |  newsweek.comN
Treatment Trials in Alzheimer's Disease
September 30, 2024  |  msn.comhttps://www.msn.com/en-au/health/other/treatment-trials-in-alzheimer-s-disease/ar-BB1mwHGY
Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine
June 20, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/06/20/2901487/0/en/vaxxinity-ub-312-parkinson-s-trial-results-published-in-nature-medicine.html
See More Vaxxinity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vaxxinity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vaxxinity and other key companies, straight to your email.

About Vaxxinity

Vaxxinity (OTCMKTS:VAXX) Inc. is a biotechnology company focused on developing vaccines and immunotherapies for chronic diseases, including neurodegenerative conditions. The company’s approach is designed to stimulate the body’s immune system to target disease-related proteins or pathways, with the goal of addressing underlying disease biology rather than treating symptoms alone.

Vaxxinity’s research and development pipeline has included UB-311, an investigational vaccine targeting amyloid beta for Alzheimer’s disease, and UB-312, an investigational vaccine designed to target abnormal alpha-synuclein associated with Parkinson’s disease and other synucleinopathies. The company has also pursued programs in other chronic conditions, including migraine and metabolic or endocrine disorders. These products remain investigational and are subject to clinical testing and regulatory review.

The company was formerly known as United Neuroscience and adopted the Vaxxinity name as it broadened its focus on immune-based medicines. Vaxxinity is headquartered in the United States and has conducted development activities through international clinical and research collaborations. Mei Mei Hu, a co-founder of the company, has served as its chief executive officer.

View Vaxxinity Profile
Earnings Tools